ClinicalTrials.gg
CompletedNCT02723331Updated Jul 1, 2025Results posted

Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates

A Phase 2 interventional study of Nab paclitaxel and Gemcitabine in Pancreatic Cancer, Pancreatic Adenocarcinoma and Pancreas Ductal Adenocarcinoma, sponsored by Academic Thoracic Oncology Medical Investigators Consortium. Completed at 4 sites in United States. Open to participants aged 18 Years to 101 Years. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Academic Thoracic Oncology Medical Investigators Consortium · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 101 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms — 22 open to participants now, 33 under way, 4 of them phase 3. Albumin-Bound Paclitaxel · Pancreatic Neoplasms.

Enrollment
64th of 130
48 · median 47
Started
2016
with 6 others
Phase 2
69 of 130
14 open now
Registered
53rd of 130
by date

Among the 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms, this one is the 64th largest by enrollment, is one of 7 that started in 2016, is one of 69 in phase 2, and was the 53rd registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

22 of the 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 745 Pancreatic Neoplasms studies recruiting now, 478 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 101 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

The objective of this study is to estimate the R0 resection rate in patients with Resectable Pancreatic Ductal Adenocarcinoma (R-PDAC) as well as those with Resectable Pancreatic Ductal Adenocarcinoma (BR-PDAC) independently in response to neoadjuvant sequential therapy of combination nab-paclitaxel and gemcitabine followed by stereotactic body radiotherapy (SBRT).

Read the detailed description

Patients in both cohorts will receive a total of 3 cycles of neoadjuvant combination chemotherapy of nab-paclitaxel and gemcitabine, followed by re-staging CT scan, if re-staging CT does not show evidence of metastatic disease. Patients will receive SBRT and definitive surgical resection. Subsequently, patients will receive 3 cycles of adjuvant combination chemotherapy of nab-paclitaxel and gemcitabine. Each cycle of combination chemotherapy will be a total of 4 weeks. Patients will be evaluated for response at completion of the 3 cycles of neoadjuvant combination chemotherapy with CT scans of chest, abdomen and pelvis. Patients will undergo surveillance CT scan at 3-month intervals until evidence of disease progression.

03

Conditions studied

  • Pancreatic Cancer
  • Pancreatic Adenocarcinoma
  • Pancreas Ductal Adenocarcinoma

Keywords

  • Stereotactic Body Radiation Therapy
  • Perioperative Therapy
  • Resectable Pancreas Ductal Adenocarcinoma
  • Borderline Resectable Pancreas Ductal Adenocarcinoma
  • Nab-paclitaxel
  • Abraxane
  • Gemcitabine
  • Neoadjuvant Therapy
  • Adjuvant Therapy
04

Who can participate

Ages eligible
18 Years to 101 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed resectable or borderline resectable pancreatic adenocarcinoma.
  2. No evidence of distant representing stage IV metastatic disease.
  3. R-PDAC: No evidence of distant metastasis and tumor mass showing no extension to superior mesenteric artery (SMA) and hepatic artery. There must be a clearly defined fat plane between SMA and celiac axis. Patent superior mesenteric vein (SMV/portal vein (PV) with no distortion of venous architecture.
  4. BR-PDAC: defined as localized PDAC with 1 or more of the following features: a) an interface between the primary tumor and superior mesenteric vein (SMV)-portal vein (PV) measuring 180o or greater of the circumference of the vein wall, and/or b) short-segment occlusion of the SMV-PV with normal vein above and below the level of obstruction that is amenable to resection and venous reconstruction and/or c) short-segment interface of any degree between tumor and hepatic artery with normal artery proximal and distal to the interface that is amenable to resection and arterial reconstruction and/or d) an interface between the tumor and SMA or celiac trunk measuring less than 180o of the circumference of the artery wall.
  5. Age > 18 years old
  6. (ECOG) performance status of 0 or 1
  7. Patients must have adequate bone marrow function:

    • >100,000 cells/mm3
    • > 9.0 g/dL
    • > 1,500 cells/mm3
  8. Patients must have adequate liver function:

    • (AST) and Alanine Aminotransferase (ALT) \< 2.5 X
    • Alkaline phosphatase \< 2.5 X upper limit of normal, unless bone metastasis is present in the absence of liver metastasis
    • Total \< 1.5 mg/dL
  9. Patients must have adequate renal function: creatinine \<1.5 mg/dL is recommended; however, institutional norms are acceptable. Creatinine within institutional limits of normal or (CrCl) > 50 mL/min calculated using the Cockcroft-Gault equation.
  10. Women of and sexually active males must use an effective method during treatment and for three months after completing treatment.
  11. Negative serum or urine β-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of childbearing potential.
  12. Patients must have \< Grade 2 pre-existing peripheral neuropathy (per 4.03).
  13. Ability to understand and willingness to sign a written .

Exclusion criteria

Exclusion Criteria:

  1. Patients with locally advanced surgically unresectable PDAC.
  2. Patients with evidence of distant PDAC.
  3. Prior chemotherapy or radiation therapy of any kind for treatment of pancreas adenocarcinoma.
  4. Prior major surgery within 4 weeks of starting study drug administration.
  5. Patient unable or not willing to perform all study related and blood draws for exploratory endpoints will not be enrolled on study as all study related procedures are mandatory.
  6. Concomitant treatment with full dose warfarin (coumadin) is NOT allowed. However, treatment with low molecular weight heparin (LMWH) (such as enoxaparin or dalteparin) or rivaroxaban is allowed. Patients on full dose warfarin (coumadin) must be transitioned to either LMWH or rivaroxaban prior to administration of any study related drugs.
  7. Recent or ongoing gastrointestinal disorder (e.g., malabsorption, bleeding, inflammation, emesis, diarrhea >grade 1).
  8. Patients with clinically significant cardiac disease ( Classification III or IV and cardiac arrhythmias not well controlled with medication), or myocardial infarction within the previous six months.
  9. Serious, uncontrolled, concurrent infection(s) requiring antibiotics.
  10. Pregnant or breastfeeding women: positive pregnancy test within 7 days of starting treatment.
  11. Treatment for other carcinomas within the last five years, except cured non-melanoma skin and treated in-situ cervical cancer.
  12. Participation in any drug study within 4 weeks preceding the start of study treatment.
  13. Patients with external biliary drains.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Nab-paclitaxel and Gemcitabine for R-PDAC

    Nab-paclitaxel and gemcitabine, for R-PDAC patients enrolled in this trial, will be given in combination as neoadjuvant combination chemotherapy, followed by SBRT. This is will be followed up by surgical resection and an additional combination chemotherapy of nab-paclitaxel and gemcitabine as adjuvant chemotherapy.

    Drug: Nab paclitaxel · Drug: Gemcitabine

  • Experimental
    Nab-paclitaxel and Gemcitabine for BR-PDAC

    Nab-paclitaxel and gemcitabine, for BR-PDAC patients enrolled in this trial, will be given in combination as neoadjuvant combination chemotherapy, followed by SBRT. This is will be followed up by surgical resection and an additional combination chemotherapy of nab-paclitaxel and gemcitabine as adjuvant chemotherapy.

    Drug: Nab paclitaxel · Drug: Gemcitabine

Interventions

  • Nab-paclitaxel and gemcitabine, for R-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.

    Also known as: Abraxane

  • Nab-paclitaxel and gemcitabine, for BR-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.

    Also known as: Gemzar

06

What researchers measure

Primary outcomes

  1. R0 Resection Rates in Each Cohort as Measured by Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins

    R0 resection rates will be measured in patients with resectable PDAC and with patients with borderline-resectable PDAC, independently in response to neoadjuvant sequential therapy of combination of nab-paclitaxel and gemcitabine and SBRT, as perioperative therapy. R0 resection is determined by macroscopically complete tumor removal with negative microscopic surgical margins in the bile duct, pancreatic parenchyma, and superior mesenteric artery (SMA).

    Time frame: at the time of surgery

Secondary outcomes

  1. Number of Participants With Treatment Related Adverse Events as Assessed by CTCAE v.4.03

    Time frame: 24 months

  2. Median Overall Survival

    Overall survival will be assessed for all participants

    Time frame: Up to 74 months

07

Results

Posted Feb 14, 2024

Participant flow

Participant flow — Overall Study
MilestoneNab-paclitaxel/Gemcitabine for R-PDACNab-paclitaxel/Gemcitabine for BR-PDAC
Started1929
Completed35
Not completed1624

Outcome measures

PrimaryR0 Resection Rates in Each Cohort as Measured by Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins

R0 resection rates will be measured in patients with resectable PDAC and with patients with borderline-resectable PDAC, independently in response to neoadjuvant sequential therapy of combination of nab-paclitaxel and gemcitabine and SBRT, as perioperative therapy. R0 resection is determined by macroscopically complete tumor removal with negative microscopic surgical margins in the bile duct, pancreatic parenchyma, and superior mesenteric artery (SMA).

Time frame:
at the time of surgery
Reported as:
Number · participants with resectable PDAC
R0 Resection Rates in Each Cohort as Measured by Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins
participants with resectable PDACNab-paclitaxel/Gemcitabine for R-PDACNab-paclitaxel/Gemcitabine for BR-PDAC
R0 Resection Rates in Each Cohort as Measured by Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins99
SecondaryNumber of Participants With Treatment Related Adverse Events as Assessed by CTCAE v.4.03
Time frame:
24 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment Related Adverse Events as Assessed by CTCAE v.4.03
ParticipantsNab-paclitaxel/Gemcitabine for R-PDACNab-paclitaxel/Gemcitabine for BR-PDAC
Number of Participants With Treatment Related Adverse Events as Assessed by CTCAE v.4.031929
SecondaryMedian Overall Survival

Overall survival will be assessed for all participants

Time frame:
Up to 74 months
Reported as:
Median · months
Median Overall Survival
monthsNab-paclitaxel/Gemcitabine for R-PDACNab-paclitaxel/Gemcitabine for BR-PDAC
Median Overall Survival17.4 (5.2 to 53.6)15.5 (1 to 73.7)

Adverse events

Collected over Up to 74 months. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nab-paclitaxel/Gemcitabine for R-PDAC18/19 (94.7%)10/19 (52.6%)19/19 (100%)
Nab-paclitaxel/Gemcitabine for BR-PDAC26/29 (89.7%)17/29 (58.6%)29/29 (100%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventNab-paclitaxel/Gemcitabine for R-PDACNab-paclitaxel/Gemcitabine for BR-PDAC
Abdominal PainGastrointestinal disorders2/193/29
Biliary ObstructionHepatobiliary disorders2/191/29
FeverGeneral disorders1/192/29
DyspneaRespiratory, thoracic and mediastinal disorders0/192/29
Acute Kidney InjuryRenal and urinary disorders1/190/29
Alanine Aminotransferase IncreasedInvestigations1/190/29
AnemiaBlood and lymphatic system disorders1/190/29
Chest PainCardiac disorders1/190/29
CholangitisHepatobiliary disorders1/191/29
CholecystitisHepatobiliary disorders1/190/29
Most frequent other events
Showing 10 of 116
Most frequent other events
EventNab-paclitaxel/Gemcitabine for R-PDACNab-paclitaxel/Gemcitabine for BR-PDAC
FatigueGeneral disorders16/1922/29
NeutropeniaBlood and lymphatic system disorders11/1920/29
AnemiaBlood and lymphatic system disorders13/1918/29
NauseaGastrointestinal disorders13/1916/29
Abdominal PainGastrointestinal disorders12/1911/29
ConstipationGastrointestinal disorders10/1914/29
DiarrheaGastrointestinal disorders10/1913/29
LeukopeniaInvestigations9/1911/29
NeuropathyNervous system disorders9/1912/29
FeverGeneral disorders8/198/29

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Nab-paclitaxel and Gemcitabine for R-PDACNab-paclitaxel and Gemcitabine for BR-PDACTotal
<=18 years000
Between 18 and 65 years5914
>=65 years142034
Age, Continuous
Age, Continuous(years)Nab-paclitaxel and Gemcitabine for R-PDACNab-paclitaxel and Gemcitabine for BR-PDACTotal
Mean68.35 ± 8.368.4 ± 8.868.4 ± 8.5
Sex: Female, Male
Sex: Female, Male(Participants)Nab-paclitaxel and Gemcitabine for R-PDACNab-paclitaxel and Gemcitabine for BR-PDACTotal
Female111526
Male81422
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nab-paclitaxel and Gemcitabine for R-PDACNab-paclitaxel and Gemcitabine for BR-PDACTotal
Hispanic or Latino437
Not Hispanic or Latino152641
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nab-paclitaxel and Gemcitabine for R-PDACNab-paclitaxel and Gemcitabine for BR-PDACTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander101
Black or African American033
White162440
More than one race000
Unknown or Not Reported224
Region of Enrollment
Region of Enrollment(participants)Nab-paclitaxel and Gemcitabine for R-PDACNab-paclitaxel and Gemcitabine for BR-PDACTotal
United States192948
08

Study locations

4 sites
  • Mayo Clinic Hospital
    Scottsdale, Arizona 85259, United States
  • University of Arizona
    Tucson, Arizona 85724, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • New York University
    New York, New York 10012, United States
09

References and documents

Publications

  • Cohen DJ, Goldberg JD, Leichman L, Hochman T, Newman E, Du K, Megibow A, Oberstein P, Al-Rajabi R, Scott AJ, Bekaii-Saab T, Messersmith WA, Weekes C. Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study. Oncologist. 2025 Oct 1;30(10):oyaf271. doi: 10.1093/oncolo/oyaf271. PubMed 40972532 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Dec 2022, 71 months.

Results were first posted in Feb 2024, 1 year 2 months after primary completion. A results delay was requested in May 2023.

Of 69 industry-sponsored phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 71 months is above that.

Counting every sponsor, half of 393 studies reached it within 57 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2016
First posted
Mar 30, 2016
StartActual
Dec 30, 2016
Primary completionActual
Dec 8, 2022
CompletionActual
Dec 28, 2022
Results delay requested
May 9, 2023
Results first posted
Feb 14, 2024
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02723331
Lead sponsor
Academic Thoracic Oncology Medical Investigators Consortium
Responsible party
Sponsor
First posted
Mar 30, 2016
Start date
Dec 30, 2016
Primary completion
Dec 8, 2022
Completion
Dec 28, 2022
Results posted
Feb 14, 2024
Last update
Jul 1, 2025

Study contacts

Wells Messersmith, MD
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Albumin-Bound Paclitaxel · Gemcitabine

Start the discussion